162744-55-0

Usage

Uses

Used in Pharmaceutical Industry:
(4-bromo-2,3-difluorophenyl)methanol is used as an intermediate in the synthesis of various organic compounds for the development of new drugs. Its unique structure allows it to be a key component in the creation of pharmaceuticals that target a range of diseases and medical conditions.
Used in Agrochemical Production:
In the agrochemical industry, (4-bromo-2,3-difluorophenyl)methanol is utilized as a building block in the production of compounds designed to protect crops and enhance agricultural yields. Its chemical properties make it suitable for the development of effective and targeted agrochemicals.
Used in Organic Chemistry Research:
(4-bromo-2,3-difluorophenyl)methanol is employed as a research compound in organic chemistry, where it aids in the exploration of new synthetic pathways and the discovery of novel chemical reactions. Its reactivity and structural features contribute to the advancement of knowledge in organic chemistry.
Used in Drug Development:
(4-bromo-2,3-difluorophenyl)methanol is used as a precursor in drug development for the treatment of various diseases. Its potential applications in medicinal chemistry make it a valuable asset in the design and synthesis of innovative therapeutic agents.

Upstream product

• 644985-24-0 4-bromo-2,3-difluoro-benzaldehyde 
• 156682-52-9 1,4-dibromo-2,3-difluoro-benzene 
• 867366-94-7 (2,3-difluoro-1,4-phenylene)bis(trimethylsilane) 
• 367-11-3 ortho-difluorobenzene 
• 194804-91-6 4-bromo-2,3-difluoro-benzoic acid 

Downstream Products

• 887586-48-3 2-(4-bromo-2,3-difluorophenyl)acetic acid 
• 1627857-25-3 2-(4-bromo-2,3-difluorophenyl)acetonitrile 
• 1378868-45-1 (4-((N-(2-(4-chlorophenyl)-5-cyclopropyl-3-(methylcarbamoyl)pyrazolo[1,5-a]pyridin-6-yl)methylsulfonamido)methyl)-2,3-difluorophenyl)boronic acid 
• 1378869-19-2 6-(N-(4-bromo-2,3-difluorobenzyl)methylsulfonamido)-2-(4-chlorophenyl)-5-cyclopropyl-N-methylpyrazolo[1,5-a]pyridine-3-carboxamide 
• 1378868-43-9 (4-((N-(3-carbamoyl-5-cyclopropyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-6-yl)methylsulfonamido)methyl)-2,3-difluorophenyl)boronic acid 
• 1378869-12-5 6-(N-(4-bromo-2,3-difluorobenzyl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-3-carboxamide 
• 1378868-42-8 (4-((N-(5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)pyrazolo[1,5-a]pyridin-6-yl)methylsulfonamido)methyl)-2,3-difluorophenyl)boronic acid 
• 1378869-11-4 6-(N-(4-bromo-2,3-difluorobenzyl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-N-methylpyrazolo[1,5-a]pyridine-3-carboxamide 
• 162744-56-1 1-bromo-4-(bromomethyl)-2,3-difluorobenzene 

Relevant academic research and scientific papers

NOVEL ANTIBIOTICS AND METHODS OF USING SAME

The present invention includes novel 3,6-diazabicyclo[3.1.1]heptane antibiotic compounds and any salts or solvates thereof. The present invention further includes methods of preparing such compounds, and methods of treating bacterial infection in a subjec

NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

PYRIDINE DERIVATIVES AS REARRANGED DURING TRANSFECTION (RET) KINASE INHIBITORS

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.